Why Immunotherapy Fails in Fibrolamellar Carcinoma And…

Why Immunotherapy Fails in Fibrolamellar Carcinoma And What May Fix It Fibrolamellar carcinoma is one of the harder conversations in hepatology and oncology. It affects primarily children and young adults. It is rare, around 2% of liver cancers. It is frequently diagnosed after metastasis. And immune checkpoint inhibitors, which have transformed outcomes in hepatocellular carcinoma, have largely failed in this disease. Until now, nobody fully understood why. A study published in Gastroenterology has mapped the mechanism and identified an FDA-approved drug that may overcome it. Using single-nucleus transcriptomics, isolating and sequencing the nuclei of individual cells within tumour tissue, the researchers constructed a detailed picture of the fibrolamellar tumour microenvironment. What they found was precise and surprising. The characteristic fibrous bands that define fibrolamellar carcinoma, the feature that gives the tumour its name, are produced by stellate cells that have been reprogrammed by the cancer. These altered stellate cells do more than produce fibrous proteins. They release chemokine si